Stereotactic Hypofractionated Irradiation for Metastatic, Inoperable, and Recurrent Malignancies: A Modern Necessity, rather than a Luxury

Table 6

Evidence for the use of SABR in adrenal metastases.

Study	Remarks	Conclusions
Torok et al. [65]	Retrospective analysis of 9 adrenal metastases treated with SABR (16 Gy × 1 Fc or 8–12 Gy × 3 Fc).	Observed 1 complete response, 2 partial responses, and 5 stable lesions. Only one progressive lesion. Safety established with no grade-3/4 toxicities.
Scorsetti et al. [66]	Prospective study of 34 patients with adrenal metastases to assess tolerability and clinical outcomes.	LC of 66% and 32%, at 1 and 2 years, respectively. No incidence of grade ≥3 toxicity.

Fc: fraction; LC: local control.